Jiangsu Sihuan Bioengineering Co., Ltd

000518.SZ

000518.SZJiangsu Sihuan Bioengineering Co., Ltd

Shenzhen

2.02

CNY

-0.01

(-0.49%)

-0.05EPS

-40.40P/E

2.08BMarket Cap

May 21Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE0000001P8

Return %

Stock

S&P500

-28.87

26.92

-39.88

27.56

-39.88

87.11

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.24	0.26	0.2	0.23	0.23	0.31	0.34	0.38	0.41	0.49	0.34	0.26	0.23	0.21
Basic EPS, GAAP	-0.01	0.01	-0.07	0.01	-0.07	- -	0.01	-0.03	0.01	0.03	-0.03	-0.05	-0.07	-0.05
Free Cash Flow per Basic Share	-0.02	-0.01	-0.03	-0.09	-0.16	-0.01	-0.03	0.02	0.04	0.09	-0.01	- -	-0.01	-0.01
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	0.65	0.66	0.59	0.6	0.53	0.53	0.54	0.51	0.52	0.55	0.52	0.47	0.4	0.39
Tangible Book Value per Share	0.72	0.64	0.61	0.6	0.53	0.52	0.61	0.59	0.59	0.62	0.59	0.53	0.47	0.46
Basic Weighted Avg Shares	1,028	1,027	1,029	1,027	1,030	1,040	1,027	1,029	1,031	1,030	1,029	1,029	1,030	1,023
Sales/Revenue/Turnover	244	262	209	241	238	327	346	396	418	505	351	270	235	220
Operating Margin (%)	6.24	7.99	-8.05	16.16	2.34	6.61	3.67	-4.36	9.61	6.92	-6.61	-14.44	-21.14	-13.1
Depreciation Expense	24	27	26	22	24	27	19	17	19	18	24	25	25	- -
Net Income, GAAP	-6	10	-71	6	-74	4	7	-29	14	27	-35	-49	-75	-49
Effective Tax Rate (%)	47.75	31.38	- -	2,202.23	- -	56.07	36.73	- -	37.17	24.1	- -	- -	- -	- -
Profit Margin (%)	-2.44	3.84	-33.88	2.47	-31.3	1.37	2.11	-7.44	3.43	5.4	-9.91	-18.06	-31.97	-22.09
Working Capital	454	377	364	257	234	271	516	481	502	527	500	449	391	387
LT Debt	- -	- -	2	- -	- -	- -	- -	- -	- -	35	31	28	26	27
Total Equity	916	830	731	722	609	611	676	643	660	685	647	593	513	501
Return on Invested Capital (%)	0.94	1.72	- -	-117.15	- -	1.53	1.21	- -	3.84	3.92	- -	- -	- -	- -
Return on Capital (%)	-1.67	0.69	- -	-10.62	- -	1.56	0.82	- -	2.15	4.34	- -	- -	- -	- -
Return on Common Equity (%)	-0.88	1.49	-10.94	0.97	-12.84	0.82	1.32	-5.46	2.69	4.94	-6.34	-9.62	-16.9	-11.54

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	3.19%	-7.97%	-12.86%
Net Income, GAAP	-219.64%	-38.23%	54.26%
Free Cash Flow	55.51%	39.14%	81.89%
Total Cash Common Dividend	30.51%	-3.17%	6.8%
Total Equity	-3.18%	-4.19%	-13.6%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Yu Guo
Full Time Employees: 282
Sector: Healthcare
Industry: Biotechnology
Address: No. 7 Binjiang East Road Jiangyin People's Republic of China 214400
IPO Date: Invalid Date
Website: www.000518shsw.com
Business: Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.

	Dec'23	Mar'24	Jun'24
ST Debt	21	22	21
LT Borrowings	- -	- -	- -
LT Finance Leases	26	26	27
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,030	1,030	1,030
Market Capitalization	3,421	2,691	2,026

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.24	0.26	0.2	0.23	0.23	0.31	0.34	0.38	0.41	0.49	0.34	0.26	0.23	0.21
Basic EPS, GAAP	-0.01	0.01	-0.07	0.01	-0.07	- -	0.01	-0.03	0.01	0.03	-0.03	-0.05	-0.07	-0.05
Free Cash Flow per Basic Share	-0.02	-0.01	-0.03	-0.09	-0.16	-0.01	-0.03	0.02	0.04	0.09	-0.01	- -	-0.01	-0.01
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	0.65	0.66	0.59	0.6	0.53	0.53	0.54	0.51	0.52	0.55	0.52	0.47	0.4	0.39
Tangible Book Value per Share	0.72	0.64	0.61	0.6	0.53	0.52	0.61	0.59	0.59	0.62	0.59	0.53	0.47	0.46
Basic Weighted Avg Shares	1,028	1,027	1,029	1,027	1,030	1,040	1,027	1,029	1,031	1,030	1,029	1,029	1,030	1,023
Sales/Revenue/Turnover	244	262	209	241	238	327	346	396	418	505	351	270	235	220
Operating Margin (%)	6.24	7.99	-8.05	16.16	2.34	6.61	3.67	-4.36	9.61	6.92	-6.61	-14.44	-21.14	-13.1
Depreciation Expense	24	27	26	22	24	27	19	17	19	18	24	25	25	- -
Net Income, GAAP	-6	10	-71	6	-74	4	7	-29	14	27	-35	-49	-75	-49
Effective Tax Rate (%)	47.75	31.38	- -	2,202.23	- -	56.07	36.73	- -	37.17	24.1	- -	- -	- -	- -
Profit Margin (%)	-2.44	3.84	-33.88	2.47	-31.3	1.37	2.11	-7.44	3.43	5.4	-9.91	-18.06	-31.97	-22.09
Working Capital	454	377	364	257	234	271	516	481	502	527	500	449	391	387
LT Debt	- -	- -	2	- -	- -	- -	- -	- -	- -	35	31	28	26	27
Total Equity	916	830	731	722	609	611	676	643	660	685	647	593	513	501
Return on Invested Capital (%)	0.94	1.72	- -	-117.15	- -	1.53	1.21	- -	3.84	3.92	- -	- -	- -	- -
Return on Capital (%)	-1.67	0.69	- -	-10.62	- -	1.56	0.82	- -	2.15	4.34	- -	- -	- -	- -
Return on Common Equity (%)	-0.88	1.49	-10.94	0.97	-12.84	0.82	1.32	-5.46	2.69	4.94	-6.34	-9.62	-16.9	-11.54

Jiangsu Sihuan Bioengineering Co., Ltd

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Growth Rates

(avg. rate of change)

Working Capital

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

	Dec'23	Mar'24	Jun'24
Total Current Assets	509	506	506
Accounts Receivable, Net	70	66	68
Cash, Cash Equivalents & STI	19	17	11
Inventories	409	410	410
Total Current Liabilities	118	115	118
Payables & Accruals	- -	- -	- -
ST Debt	21	22	21
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	-0.02	- -	- -	- -	-0.05
2023	-0.02	- -	- -	- -	-0.07
2024	- -	- -	- -	- -	- -